Tubulin Inhibitors
13 drugsStrategic Insights
ℹ️ How we calculate- Validated target with strong trial activity and 80% attractiveness score.
Human Genetic Evidence Strong
Evidence Across Diseases
7 totalGWAS and other genetic studies link TUBB to 7 diseases.
Understanding these scores
Association Score (0-1): Combines all evidence types (genetic, literature, drugs, animal models). Higher = more evidence linking target to disease. This is a ranking heuristic, not a confidence score.
L2G Score: Open Targets uses a machine learning model (Locus-to-Gene) to predict which gene is causal at each GWAS locus. L2G=0.5 means ~50% probability of being the causal gene. Only associations with L2G > 0.05 are included.
Odds Ratio (OR): From gene burden studies (UK Biobank, AstraZeneca PheWAS). Measures how loss-of-function variants affect disease risk. OR<1 = protective (inhibiting target may help), OR>1 = risk (losing function causes disease).
Beta (β): Effect size for continuous traits. β<0 = protective, β>0 = risk.
Clinical Translation (~1.8x): Based on Nelson et al. 2015: drug targets with genetic evidence have ~2x higher success rates in clinical trials. We estimate: Strong support (score ≥0.7) → ~1.8x, Moderate (0.3-0.7) → ~1.3x, Weak → baseline.
Colocalization (H4): Tests whether a GWAS signal and an eQTL/pQTL signal share the same causal variant. H4 is the posterior probability that both traits are associated AND share a causal variant. H4 > 0.8 = strong evidence that gene expression/protein levels drive disease risk. This links genetic variation → gene expression → disease, supporting the target-disease connection.
Top Drugs
| Drug | Company | Approved | Indications |
|---|---|---|---|
| HALAVEN | EISAI INC | 2010 | 2 |
| ERIBULIN MESYLATE | LONG GROVE PHARMS | 2024 | 2 |
| IXEMPRA KIT | R-PHARM US LLC | 2007 | 1 |
| BLENREP | GSK | 2025 | 1 |
| KADCYLA | Roche | 2013 | 1 |
| TIVDAK | SEAGEN | 2021 | 1 |
| EMRELIS | AbbVie | 2025 | 1 |
| JEVTANA KIT | Sanofi | 2010 | 1 |
| PADCEV | ASTELLAS | 2019 | - |
| ABRAXANE | Bristol-Myers Squibb | 2005 | - |
Drug Modality Landscape
Modalities
Routes of Administration
Tubulin is druggable by both biologics (7) and small molecules (6), indicating broad therapeutic accessibility.
📈 Modality Evolution
Small molecules pioneered Tubulin targeting (2005), with adcs entering more recently (2011).
Clinical Trials 4,347 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 1314 | 631 | 305 | 371 | 67% |
| Phase 2 | 2147 | 844 | 373 | 914 | 69% |
| Phase 3 | 818 | 317 | 83 | 412 | 79% |
| Phase 4 | 68 | 40 | 3 | 24 | 93% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
8 Phase 3 trials testing approved Tubulin drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting Tubulin. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Drug Approval Timeline (2005 - 2025)
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 12 companies competing
- • Market share by company
Full Drug Portfolio
- • All 13 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 13-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 2897 clinical trials targeting Tubulin.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities